Simplex Trading’s Design Therapeutics DSGN Stock Holding History

Simplex Trading’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.34K	Buy	+300	New	+$3.74K	﹤0.01%	8259
2026 Q1	–	Sell	-600	Closed	-$5.63K	–	9309
2025 Q4	$5.63K	Sell	600 -600	-50%	-$4.7K	﹤0.01%	7366
2025 Q3	$9K	Buy	+1,200	New	+$6.01K	﹤0.01%	7951
2024 Q4	–	Sell	-1,300	Closed	-$6K	–	8737
2024 Q3	$6K	Buy	1,300 +800	+160%	+$3.76K	﹤0.01%	7503
2024 Q2	$1K	Hold	500	–	–	﹤0.01%	8452
2024 Q1	$2K	Buy	+500	New	+$1.33K	﹤0.01%	8383
2023 Q4	–	Sell	-1,100	Closed	-$2K	–	9004
2023 Q3	$2K	Buy	+1,100	New	+$5.13K	﹤0.01%	8070
2023 Q2	–	Sell	-900	Closed	-$5K	–	9179
2023 Q1	$5K	Sell	900 -4,000	-82%	-$29.9K	﹤0.01%	8027
2022 Q4	$50K	Sell	4,900 -45,700	-90%	-$619K	﹤0.01%	5894
2022 Q3	$846K	Buy	+50,600	New	+$1.01M	﹤0.01%	2848

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Simplex Trading's DSGN Position: Q2 2026 in Review

Simplex Trading opened a new position in Design Therapeutics (DSGN) in Q2 2026: 172 shares worth $2.49K. The stake represents ﹤0.01% of the portfolio and ranks #8553 among its holdings. This is a return to the name: Simplex Trading previously reported a position in DSGN as recently as Q1 2025.

Simplex Trading first reported a position in DSGN in Q1 2023 and has held it in 10 quarters since. The position peaked at $40K in Q3 2024. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Simplex Trading held 172 shares of Design Therapeutics worth $2.49K as of Q2 2026.
Design Therapeutics was a new Simplex Trading position in Q2 2026.
Design Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8553 holding.
Simplex Trading first reported a position in Design Therapeutics in Q1 2023 and has held it in 10 quarters since.
Simplex Trading's Design Therapeutics position peaked at $40K in Q3 2024.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.